AtriCure (NASDAQ:ATRC) Price Target Raised to $50.00 at Piper Sandler

AtriCure (NASDAQ:ATRC) had its price objective upped by Piper Sandler from $40.00 to $50.00 in a research report released on Thursday,Benzinga reports. Piper Sandler currently has an overweight rating on the medical device company’s stock.

Several other analysts also recently commented on ATRC. UBS Group increased their target price on AtriCure from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $51.00 price target on shares of AtriCure in a report on Thursday. Stifel Nicolaus lifted their price objective on AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday. JPMorgan Chase & Co. boosted their target price on AtriCure from $40.00 to $51.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Canaccord Genuity Group raised their price target on shares of AtriCure from $61.00 to $66.00 and gave the company a “buy” rating in a report on Thursday. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $51.56.

AtriCure Trading Down 6.5 %

NASDAQ:ATRC opened at $39.59 on Thursday. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -47.70 and a beta of 1.46. The company has a quick ratio of 2.59, a current ratio of 3.62 and a debt-to-equity ratio of 0.13. The company’s 50 day moving average price is $35.52 and its 200-day moving average price is $31.17. AtriCure has a 52 week low of $18.94 and a 52 week high of $43.11.

Hedge Funds Weigh In On AtriCure

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Arcadia Investment Management Corp MI purchased a new stake in AtriCure during the third quarter valued at approximately $28,000. Heck Capital Advisors LLC bought a new stake in shares of AtriCure during the 4th quarter valued at $60,000. Venturi Wealth Management LLC increased its stake in shares of AtriCure by 1,337.6% in the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock worth $69,000 after purchasing an additional 2,100 shares in the last quarter. KBC Group NV raised its holdings in AtriCure by 65.3% in the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock worth $72,000 after purchasing an additional 932 shares during the period. Finally, R Squared Ltd purchased a new position in AtriCure during the fourth quarter valued at $89,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.